TV 1380
Alternative Names: Albu-CocH; AlbuBChE; Cocaine hydrolase - Teva; Recombinant human serum albumin mutated butyrylcholinesterase; TV-1380Latest Information Update: 21 Mar 2016
Price :
$50 *
At a glance
- Originator CoGenesys
- Developer Teva Pharmaceutical Industries
- Class Antidotes; Cholinesterases; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cocaine-related disorders
Most Recent Events
- 21 Mar 2016 No recent reports on development identified - Phase-II for Cocaine abuse in Spain and USA (IM)
- 01 Oct 2014 Teva Pharmaceutical completes a phase II trial in Cocaine abuse in USA and Spain (NCT01887366)
- 17 Sep 2013 Phase-II clinical trials in Cocaine abuse in Spain (IM)